Introduction Lorlatinib, also known by its brand name Lorbrena, is a third-generation tyrosine kinase inhibitor (TKI) designed to treat ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive NSCLC. Unlike earlier…